YorkBridge Wealth Partners’s Aimmune Therapeutics AIMT Stock Holding History

YorkBridge Wealth Partners’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-500	Closed	-$10K	–	736
2019 Q2	$10K	Hold	500	–	–	﹤0.01%	571
2019 Q1	$11K	Hold	500	–	–	0.01%	585
2018 Q4	$12K	Hold	500	–	–	0.01%	553
2018 Q3	$13K	Hold	500	–	–	0.01%	582
2018 Q2	$13K	Sell	500 -500	-50%	-$15.3K	0.01%	597
2018 Q1	$31K	Hold	1,000	–	–	0.01%	427
2017 Q4	$35K	Buy	+1,000	New	+$32.3K	0.02%	411

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YorkBridge Wealth Partners's AIMT Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 500 shares — an estimated $10K sold.

YorkBridge Wealth Partners first reported a position in AIMT in Q4 2017 and held it in 7 quarters. The position peaked at $35K in Q4 2017. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

YorkBridge Wealth Partners reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
YorkBridge Wealth Partners sold 500 Aimmune Therapeutics shares in Q3 2019, an estimated $10K.
YorkBridge Wealth Partners first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 7 quarters.
YorkBridge Wealth Partners's Aimmune Therapeutics position peaked at $35K in Q4 2017.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.